Historically, mAbs that target antigens relevant to cancer have comprised \~50% of the mAb clinical pipeline, but the majority (19/29; 66%) of the antibodies to watch in 2013 are for non-cancer indications ([Table 1](#T1){ref-type="table"}). Of the 19 product candidates, all are either humanized (11 mAbs) or human (7 single mAbs and the mAb mixture) full-length mAbs; three are IgG2, four are IgG4, with the remainder IgG1. Four antigens, amyloid beta, proprotein convertase subtilisin/kexin type 9 (PCSK9), interleukin (IL)-5, IL-17a, are the targets of two mAbs each.

###### **Table 1.** Therapeutic antibodies in Phase 2/3 or Phase 3 clinical studies of non-cancer indications

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sponsoring company   INN or code name                      Molecular type   Target(s)                          Current phase   Phase 2/3 or 3 indications
  -------------------- ------------------------------------- ---------------- ---------------------------------- --------------- -----------------------------------------------------------------------
  Amgen                AMG 145                               Human IgG2       PCSK-9                             Phase 2/3       High cholesterol

  Regeneron; Sanofi    Alirocumab,\                          Human IgG1       PCSK-9                             Phase 3         High cholesterol; acute coronary syndrome
                       REGN-727, SAR236553                                                                                       

  Amgen                Romosozumab                           Humanized IgG2   Sclerostin                         Phase 3         Postmenopausal\
                                                                                                                                 osteoporosis

  Merck                Actoxumab + bezlotoxumab (MK-3415A)   Human IgG1       C. difficile enterotoxin A and B   Phase 3         C. difficile Infection

  Xoma; Servier        Gevokizumab                           Humanized IgG2   IL-1 β                             Phase 3         Non-infectious uveitis

  GlaxoSmithKline      Mepolizumab                           Humanized IgG1   IL-5                               Phase 3         Asthma; hypereosinophilic syndrome; COPD with eosinophilic bronchitis

  Teva                 Reslizumab                            Humanized IgG4   IL-5                               Phase 3         Eosinophilic asthma

  Janssen\             Sirukumab                             Human IgG1       IL-6                               Phase 3         Rheumatoid arthritis
  Research &\                                                                                                                    
  Development LLC                                                                                                                

  Regeneron; Sanofi    Sarilumab, SAR153191,\                Human IgG1       IL-6R subunit α                    Phase 3         Rheumatoid arthritis
                       REGN88                                                                                                    

  Genentech            Lebrikizumab                          Humanized IgG4   IL-13                              Phase 3         Asthma

  Eli Lilly and Co.    Ixekizumab (LY2439821)                Humanized IgG4   IL-17a                             Phase 3         Psoriasis

  Novartis\            Secukinumab                           Human IgG1       IL-17a                             Phase 3         Rheumatoid or psoriatic arthritis; ankylosing spondylitis; psoriasis
  Pharmaceuticals                                                                                                                

  Millennium\          Vedolizumab                           Humanized IgG1   alpha4/beta7 integrin              Phase 3         Ulcerative colitis; Crohn disease
  Pharmaceuticals                                                                                                                

  Eli Lilly and Co.    Tabalumab, LY2127399                  Human IgG4       BLyS                               Phase 3         SLE; rheumatoid arthritis, MM

  Biocon               Itolizumab                            Humanized IgG1   CD6                                Phase 3         Plaque psoriasis

  Genentech            Ocrelizumab                           Humanized IgG1   CD20                               Phase 3         Multiple sclerosis

  UCB                  Epratuzumab                           Humanized IgG1   CD22                               Phase 3         SLE

  Hoffmann-LaRoche     Gantenerumab                          Human IgG1       Amyloid beta                       Phase 3         Alzheimer disease

  Eli Lilly and Co.    Solanezumab                           Humanized IgG1   Amyloid beta                       Phase 3         Alzheimer disease
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table compiled from information available as of November 15, 2012. IL, interleukin ; MM, multiple myeloma ; PCSK9, proprotein convertase subtilisin/kexin type; SLE, systemic lupus erythematosus

The IgG2 AMG 145 and IgG1 alirocumab, both of which target PCSK9, are undergoing assessments of safety and efficacy in patients with hypercholesterolemia. A Phase 2/3 study to determine the safety, tolerability, and efficacy of AMG 145 in subjects with homozygous familial hypercholesterolemia was initiated in March 2012 and is due for completion in May 2013. Results from several Phase 1 and 2 studies of AMG 145 have recently been reported.[@R1]^-^[@R4] In July 2012, Sanofi and Regeneron announced the initiation of the ODYSSEY program, which is a series of Phase 3 clinical trials of alirocumab. As of mid-November 2012, a total of eight Phase 3 studies of alirocumab were listed as recruiting on clinicaltrials.gov: ODYSSEY Mono (alirocumab compared with ezetimibe in patients with hypercholesterolemia), ODYSSEY Combo I and II (evaluates alirocumab in combination with lipid modifying therapy in patients with hypercholesterolemia at high cardiovascular risk), ODYSSEY High FH (evaluates alirocumab in combination with lipid modifying therapy in patients with familial hypercholesterolemia), ODYSSEY FHI (evaluates alirocumab in patients with familial hypercholesterolemia that is not adequately controlled), ODYSSEY Alternative (evaluates alirocumab in patients with hypercholesterolemia and cardiovascular risk who are intolerant to statins), ODYSSEY Outcomes (compares the effect of alirocumab with placebo on the occurrence of cardiovascular events in patients who have experienced an acute coronary syndrome event), and ODYSSEY Long-term (evaluated the long-term safety and tolerability of alirocumab in patients with hypercholesterolemia and cardiovascular risk). The completion dates for these studies are between November 2013 (ODYSSEY Mono) and March 2018 (ODYSSEY Outcomes).

Two anti-IL-5 mAbs, IgG1 mepolizumab and IgG4 reslizumab, are in multiple Phase 3 studies that are actively recruiting patients. Mepolizumab is currently undergoing evaluation in six Phase 3 studies; patients with asthma are being recruited for four studies, while patients with hypereosinophilic syndrome and patients with chronic obstructive pulmonary diseases and eosinophilic bronchitis are each being recruited for one study. The completion dates for these six studies range from March 2013 to December 2016. Patients are currently being recruited for a total of four Phase 3 studies of the safety and efficacy of reslizumab as a treatment for eosinophilic asthma. These four studies have estimated completion dates between June 2013 and January 2015.

IL-17a is the target of IgG4 ixekizumab and IgG1 secukinumab. Ixekizumab is undergoing evaluation as a treatment for moderate to severe psoriasis in three Phase 3 studies, UNCOVER-1, -2 and -3. These three studies have estimated completion dates between February 2018 and April 2019. Japanese patients with moderate to severe psoriasis are being recruited for an additional Phase 3 study of ixekizumab. A Phase 3 study of patients with active psoriatic arthritis was planned but had not yet started recruiting patients as of mid-November 2012. The safety and efficacy of secukinumab are being evaluated in a total of 12 Phase 3 studies listed on clinicaltrials.gov as recruiting or active but not recruiting. Seven of the 12 studies include patients with psoriasis; study completion dates range from March 2013 to May 2015. Three Phase 3 studies of secukinumab in rheumatoid arthritis (RA) patients are due for completion between August 2013 and September 2018. Two additional Phase 3 studies, one each of patients with psoriatic arthritis or ankylosing spondylitis, have estimated completion dates in July 2014.

Several of the antibodies to watch in 2013 have had setbacks in development, e.g., sarilumab, ocrelizumab. Sarilumab, a human IgG1 that targets the IL-6 receptor is currently in two Phase 3 studies as a treatment for RA. The RA-MOBILITY study (NCT01061736), which is evaluating the effects of sarilumab on top of methotrexate in RA patients, is due for completion in October 2013. A Phase 3 study started in June 2010 that evaluated the long-term safety and efficacy of sarilumab in ankylosing spondylitis patients was terminated due to lack of benefit on efficacy. Ocrelizumab, an anti-CD20 humanized IgG1, is currently in two Phase 3 studies of patients with relapsing multiple sclerosis that have estimated completion dates in June and August of 2015. The Phase 3 FEATURE study of ocrelizumab in RA patients was terminated based on analysis of results and consideration of available treatments that indicated the overall benefit to risk profile of ocrelizumab was not favorable in RA.

Ten of the antibodies to watch in 2013 are undergoing evaluation as cancer treatments ([Table 2](#T2){ref-type="table"}). Seven of the ten are full-length, unmodified mAbs; inotuzumab ozogamicin is an antibody-drug conjugate (ADC), onartuzumab comprises a Fab-Fc fusion and naptumomab estafenatox is a Fab-based immunotoxin. Naptumomab estafenatox combined with interferon (IFN)-α vs. IFN-α alone in renal cell carcinoma patients was evaluated in a Phase 2/3 study (NCT00420888). Active Biotech has indicated that they expect results of the study results to be presented in the first quarter of 2013. Several Phase 3 studies of ramucirumab are due for completion in 2013. A Phase 3 study (NCT00917384) of ramucirumab in patients with metastatic gastric or gastresophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy and the Phase 3 REACH study (NCT01140347) of ramucirumab as second-line treatment in hepatocellular carcinoma patients following first-line therapy with sorafenib have estimated completion dates in January and August 2013, respectively. Ramucirumab is also in Phase 3 studies as a treatment for breast, colorectal and non-small cell lung cancers.

###### **Table 2.** Therapeutic antibodies in Phase 2/3 or Phase 3 clinical studies of cancer indications

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sponsoring company                       INN or code name                      Molecular type           Target(s)           Current phase   Phase 2/3 or 3 indications
  ---------------------------------------- ------------------------------------- ------------------------ ------------------- --------------- --------------------------------------------------
  Active Biotech                           Naptumomab estafenatox (ABR-217620)   Murine Fab immunotoxin   5T4                 Phase 2/3       Renal cell carcinoma

  ImClone LLC                              Ramucirumab                           Human IgG1               VEGFR2              Phase 3         Gastric; liver, breast, colorectal, NSCL cancers

  Morphotek                                Farletuzumab                          Humanized IgG1           Folate receptor α   Phase 3         Ovarian cancer

  Genentech; Roche Pharma                  Obinutuzumab                          Humanized IgG1           CD20                Phase 3         Diffuse large B cell\
                                                                                                                                              lymphoma, CLL, NHL

  Bristol-Myers Squibb, Abbott             Elotuzumab                            Humanized IgG1           CD2                 Phase 3         Multiple myeloma

  Pfizer; UCB                              Inotuzumab ozogamicin                 Humanized IgG4 ADC       CD22                Phase 3         ALL; NHL

  ImClone LLC                              Necitumumab                           Human IgG1               EGFR                Phase 3         NSCL cancer

  Bristol-Myers Squibb                     Nivolumab\                            Human IgG4               PD1                 Phase 3         NSCL cancer, renal cell carcinoma
                                           (BMS*-*936558)                                                                                     

  Genentech                                Onartuzumab                           Humanized IgG1 Fab-Fc    cMet                Phase 3         NSCL cancer; gastric cancer

  CIMAB; Laboratorio Elea S.A.C.I.F. y A   Racotumomab                           Murine                   GM3                 Phase 3         NSCL cancer
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table compiled from information available as of November 15, 2012. ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; VEGFR2, vascular endothelial growth factor receptor 2

Phase 3 study results of farletuzumab in ovarian cancer may be released in 2013. In March 2012, Morphotek announced that a Phase 3 study (NCT00849667) of farletuzumab in combination with carboplatin and taxane in patients with platinum-sensitive ovarian cancer in first relapse had reached its randomization target of 1080 patients; the final data collection date for primary outcome measures was estimated as September 2012. A previous Phase 3 study (NCT00738699) of farletuzumab in combination with paclitaxel therapy in patients with platinum-resistant or refractory relapsed ovarian cancer did not meet pre-specified criteria for continuation following interim futility analysis and was terminated.

The Phase 3 SQUIRE study (NCT00981058) of gemcitabine-cisplatin chemotherapy plus necitumumab vs. gemcitabine-cisplatin chemotherapy alone in the first-line treatment of patients with Stage IV squamous non-small cell lung cancer has an estimated primary completion date of September 2013. Enrollment of the Phase 3 INSPIRE study (NCT00982111) of pemetrexed-cisplatin chemotherapy with necitumumab compared with the chemotherapy alone in the first-line treatment of patients with Stage IV nonsquamous non-small cell lung cancer was stopped because of safety concerns related to thromboembolism in the experimental study arm. Two Phase 2 studies of necitumumab as a treatment for solid tumors have estimated completion dates in July 2013.

*mAbs* looks forward to tracking the clinical study results that may be released during the year, but we also anticipate the first marketing approval of at least one therapeutic antibody in 2013. Trastuzumab emtansine, which is composed of trastuzumab (Herceptin®) conjugated to a cytotoxic drug, was given a \'priority review\' designation by the US Food and Drug Administration; a decision on the marketing application is expected by February 26, 2013. The ADC is also undergoing regulatory review by the European Medicines Agency. Results of a Phase 2 study of trastuzumab emtansine as first-line treatment in previously untreated patients with HER2-positive metastatic breast cancer indicated that the ADC provided significant improvement in progression-free survival compared with the control treatment (trastuzumab plus docetaxel) and had a favorable safety profile.[@R5]
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